Founded in 1769, Semmelweis University is the oldest medical school in Hungary. The faculty became an independent medical school after the Second World War and developed into a university teaching medicine, dentistry, pharmacy, health science, and health management, as well as physical education and sport science. The university is named after Ignác Semmelweis , the obstetrician who discovered the cause of puerperal fever in the 1840s.The university has around 10,000 students from 60 nations over five continents. Its five faculties offer courses from undergraduate to doctorate level in Hungarian, English, and German. Foreign students account for about 18% of the total community.Semmelweis University is the largest health care institution in Hungary, with over 9,000 employees covering about 6% of the health care needs of the country’s population.With a quarter of a million of books, Semmelweis University has one of the biggest and best-furnished medical-biological collections in Hungary, and among the Hungarian universities, Semmelweis produces the greatest number of publications. The university is deeply involved in the patient care of the Great-Budapest region. Of its 3000 clinical beds, 75% take part in the regional medical care and some special outpatients' departments also supply the teaching hospitals with patients needed for the training.The portrait of Maria Theresa in the Assembly Hall of the University still commemorates the founding of the Medical Faculty by the Empress of Austria-Hungary more than 230 years ago, forging a continuous link in the education and training of medical students.The name of the University honors Ignác Semmelweis, a former professor of the Medical Faculty between 1855 and 1865, who discovered the cause and prevention of puerperal fever. Semmelweis was the first Hungarian university, which started to offer international courses at the Faculty of Medicine in German in 1983. The English programs started four years later, in 1987. Nowadays, the university enrolls more than 200 new international students each year. Still, students from Germany form the majority of the international student body, although numbers from Israel, Scandinavia, Ireland and Cyprus show consistent growth in recent years.The General Medicine program is listed by the WHO and it is recognized without any licensing examinations in all European Union countries The program leading to the Doctor of Medicine degree consists of six years: two years of general medical studies, three years of clinical studies, and one year of a rotating internship. International students enrolled in the English program are mostly from the EU, Norway, Israel, Cyprus, Iran, Japan, and the USA.The Semmelweis University seeks motivated candidates for the program with a solid background in biology and chemistry. In addition to these subjects, students must pass an entrance exam in English. The application deadline is in April and the course starts in September. Entrance exams are arranged at several locations in Europe, Israel, North America, Asia, and Africa.Since 1 September 2014, the Faculty of Physical Education and Sport science has been separated from Semmelweis University and continues to operate as an independent institution under the name University of Physical Education. Wikipedia.
Agency: Cordis | Branch: H2020 | Program: ERC-STG | Phase: ERC-StG-2015 | Award Amount: 1.02M | Year: 2016
Imagine if tumor growth would be reduced and then kept in a minimal and safe volume in an automated manner and in a personalized way, i.e. cancer drug would be injected using a continuous therapy improving the patients quality of life. By control engineering approaches it is possible to create model-based strategies for health problems. Artificial pancreas is an adequate example for this, where by continuous glucose measurement device and insulin pump it is possible to improve diabetes treatment. Gaining expertise from this problem, the current proposal focuses on taming the cancer by developing an engineering-based medical therapy. The interdisciplinary approach focuses on modern robust control algorithm development in order to stop the angiogenesis process (i.e. vascular system development) of the tumor; hence, to stop tumor growth, maintaining it in a minimal, tamed form. This breakthrough concept could revitalize cancer treatment. It is the right time to do it as some investigations regarding tumor growth modeling have been already done; now, it should be refined by model identification tools and validated on animal trials. The benefit of robust control was already demonstrated in artificial pancreas; hence, it could be adapted to cancer research. The result could end with a personalized healthcare approach for drug-delivery in cancer, improving quality of life, optimizing drug infusion and minimizing treatment costs. This interdisciplinary approach combines control engineering with mathematics, computer science and medical sciences. As a result, the model-based robust control approach envisage refining the currently existing tumor growth modeling aspects, design an optimal control algorithm and extend it by robust control theory to guarantee its general applicability. Based on our research background, validation will be done first in a manually controlled way, but then in an automatic mode to propose it for further human investigations.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-23-2014 | Award Amount: 5.99M | Year: 2015
ADVOCATE brings together top principal investigators from prestigious universities, the public sector, and the private sector to address the most common diseases affecting humanity, as measured by the recent Global Burden of Disease Study. ADVOCATE strives to optimise delivery of oral health and wellbeing to the population in EU Member States. This requires a change in oral health care delivery towards prevention. The change will be achieved by developing a model that promotes a preventive rather than restorative oral health care system: The oral health care model 2020. As the oral health care delivery system is not as overly complex as other health care systems, the oral health care model 2020 may serve as a blueprint for other health care system reforms. The development of this model requires intensive information exchange and engagement of stakeholders to establish a set of key-indicators. These indicators will be used to benchmark health care performance on practice as well as system level. Two types of evidence-based indicators will be selected: Quantitative and qualitative indicators that allow measuring and influencing of either intrinsic motivation or extrinsic motivation incentives towards a patient centred, resilient and prevention oriented oral health care system. ADVOCATE will test this model in a natural environment, and provide evidence-informed policy measures towards its implementation, both for oral health care systems as well as other health care systems. Given the comprehensiveness of the topic, ADVOCATE uses a targeted approach that is entirely focused on the five major root-causes underlying the current suboptimal performance of oral health care systems. Moreover, ADVOCATE has confirmed access to data of eight European oral health care databases; it is well connected to existing initiatives and networks, and has ample support from preventive oriented industry, as exemplified by the financial support provided for the final conference.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-17-2014 | Award Amount: 6.77M | Year: 2015
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population ( 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.4.2-2 | Award Amount: 7.70M | Year: 2014
Coronary artery disease (CAD) is the leading cause of death in high-income countries. Invasive coronary angiography (ICA) is the reference standard for the diagnosis of CAD and allows immediate therapy. However, only 40% of patients undergoing ICA actually have obstructive CAD and ICA has relatively rare but considerable risks. Coronary computed tomography (CT) is the most accurate diagnostic test for CAD currently available. CT may become the most effective strategy to reduce the ca. 2 million annual negative ICAs in Europe by enabling early and safe discharge of the majority of patients with an intermediate risk of CAD. To evaluate this, we propose the DISCHARGE project that will be implemented by a multinational European consortium. The core of the project is the DISCHARGE pragmatic randomised controlled trial. The primary hypothesis will be that CT is superior to ICA for major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and stroke) after a maximum follow-up of 4 years in a selected broad population of stable chest pain patients with intermediate pretest likelihood of CAD. The trial will include 23 clinical sites from 18 European countries ensuring broad geographical representation. Comparative effectiveness research of complementing work packages include gender-related analysis, systematic review of evidence, cost-effectiveness analysis, and health-related quality of life. DISCHARGE has the capability to influence current standards and guidelines as well as coverage decisions and will raise awareness among patients, health care providers, and decision-makers in Europe about the effectiveness and cost-effectiveness of coronary CT angiography.
Agency: Cordis | Branch: FP7 | Program: BSG-SME | Phase: SME-2013-1 | Award Amount: 1.72M | Year: 2014
Cancer is the second largest cause of death and morbidity in Europe, with more than 3 million new cases diagnosed each year. The most effective treatment strategy for most forms of cancer is early detection followed by surgery. However, cancers frequently recur following surgery. For example, nearly 1 in 4 breast cancer patients will see their tumor recur after surgery. The consequences of cancer recurrence include repeat operations, delayed adjuvant treatment, increased likelihood of distant recurrence, poorer cosmetic and functional outcomes, emotional distress, and financial cost. The financial costs are staggering. Europe spends 125 billion annually on cancer care, approximately 5% of which is managing post-surgical recurrence. Tumors recur after surgery primarily due to incomplete excision of the tumor or inadequate clearance of surgical margins. Tumors fail to be completely excised because the surgeon only has the visual appearance of the tumor and palpation to differentiate malignant from benign tissue. Consequently, there is an urgent clinical and market need for improved tools to detect cancerous tissue during surgery. Real-time imaging during surgery would enable the surgeon to more accurately resect tumors and thereby reduce the likelihood of post-surgical recurrence. Cerenkov luminescence imaging (CLI) is a ground-breaking imaging modality that can provide real-time molecular imaging during surgery The CLIO consortium will develop a Cerenkov luminescence imaging device for image-guided surgery as well as imaging services for the pharmaceutical and medical device sectors. The imaging services will enable pharmaceutical and medical device clients to improve the efficacy evaluation of pharmaceutical and surgical device products. The consortium contains world-leading expertise in medical device product development, clinical and preclinical imaging, oncologic surgery, and surgical device evaluation.
Agency: Cordis | Branch: H2020 | Program: SGA-CSA | Phase: WIDESPREAD-1-2014 | Award Amount: 496.86K | Year: 2015
Existing European disparity in research and innovation performance is a barrier to competitiveness and growth. To overcome this disparity, the leading institute in molecular life sciences and three research universities of Hungary have joined forces forming a new Centre of Excellence for Molecular Medicine (HCEMM). These institutions have the necessary basic research and clinical portfolio to initiate a joint translational research program and eventually deliver high impact results. Engagement of the European Molecular Biology Laboratory and its long term experience in partnerships for molecular medicine provides guidance and technical support to achieve these goals, particularly bringing new research culture and management approaches including selection, regular evaluation and internationalization of independent groups. Joining of Hungary to EMBL by 2014 is a strong basis of this partnership. Commitment of the Hungarian Government towards establishment of HCEMM is clearly demonstrated by its coordinator role via the National Innovation Office which is responsible for research, development, innovation and the national S3 strategy. A joint management structure will be developed to assess basic research and clinical strengths of participating institutions, to identify key clinical areas of research where unmet medical needs exist and to pair basic research groups with clinical researchers to form translational research units for tackling these problems. All partners in the consortium will actively contribute to prepare a business plan of long-term sustainability and then to establish legal autonomy, location and proper resources of HCEMM. HCEMM is expected to demonstrate feasibility of the teaming concept by realizing synergistic research efforts that builds on the specific strengths of the participants and needs. Technological platforms will also be jointly established. Intense technology transfer, shared PhD and clinical research training will serve the key goals.
Agency: Cordis | Branch: H2020 | Program: MSCA-RISE | Phase: MSCA-RISE-2014 | Award Amount: 567.00K | Year: 2015
Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also within its microenvironment. Tumor angiogenesis, tumor-stroma interactions, interactions with immune cells, with the extracellular matrix and cancer stem cell niches allow for malignant cell survival and promote metastasis, the leading cause for cancer-associated mortality. Proteoglycans (PGs) and glycosaminoglycans (GAGs) structurally diverse carbohydrates of the extracellular matrix and cell surfaces - have emerged as novel biomarkers and molecular players both within tumor cells and their microenvironment, as they integrate signals from growth factors, chemokines and integrins, and cell-cell as well as matrix adhesion. Importantly, their expression is dysregulated in numerous tumor entities, and has been shown to modulate each of the hallmarks of cancer as defined by Hanahan and Weinberg (Cell 2011). We hypothesize that dysregulated function of PGs and GAGs simultaneously affects all molecular steps towards cancer metastasis as a general principle applicable to multiple tumor entities. Pharmacological modulation of their function thus emerges as an attractive multitargeted antitumoral approach which simultaneously acts at multiple levels of disease progression. Besides providing extensive knowledge transfer and training for researchers, the combined expertise of the GLYCANC consortium aims at performing a detailed structural analysis of PG and GAG glycans in disease using state-of-the art methodology, analysing their regulation via epigenetic mechanisms and microRNAs, and elucidating molecular mechanisms underlying aberrant PG and GAG function. GLYCANC will lead to a deeper understanding of glycan structures and glycan-dependent mechanisms promoting cancer progression, providing the basis for rational multitargeted anticancer approaches.
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-26-2014 | Award Amount: 4.03M | Year: 2015
In European Union approximately 5 million people suffer from psychotic disorders. Between 30-50% can be considered resistant to treatment, and 10-20% ultra-resistant. These patients present persistent positive symptomatology, require extensive periods of hospital care, and have a greater risk of excess mortality and multi-morbidity. In addition, a high proportion of the total cost for treating schizophrenia is spent on this population (Kennedy et al., 2013). Intervention strategies based on mHealth have demonstrated their ability to support and promote self-management-based strategies. Evidence from studies point to the importance of engaging patients actively in their own treatment. This active role helps to improve adherence to treatment, and to reduce persistent symptoms severity, relapses and hospitalizations (Mueser et al., 2002). m-RESIST aims to develop an intervention programme based on mHealth to allow patients suffering from resistant schizophrenia to self-manage their condition (resistant schizophrenia and its associated comorbidities, e.g. somatic disorders and addictions). This may facilitate acceptance and involvement of patients with their own treatment, as well as of caregivers. Moreover this programme could provide a new tool to the psychiatrist, psychologists working together with other health care professionals, to better monitor patients, through a personalised and optimised therapeutic process. m-resist will (1) develop and validate an mHealth solution aimed to reduce the severity of episodes and further complications; (2) involve and promote participation of patients and caregivers in the therapeutic process increasing the awareness of patient and caregiver about the nature of the illness and its consequences, benefits of treatment and needs for healthy habits and promoting an active and collaborative role with the medical team in the treatment decision-making procedure.
Szabo G.T.,Semmelweis University
Cellular and molecular life sciences : CMLS | Year: 2014
Under physiological and pathological conditions, extracellular vesicles (EVs) are present in the extracellular compartment simultaneously with soluble mediators. We hypothesized that cytokine effects may be modulated by EVs, the recently recognized conveyors of intercellular messages. In order to test this hypothesis, human monocyte cells were incubated with CCRF acute lymphoblastic leukemia cell line-derived EVs with or without the addition of recombinant human TNF, and global gene expression changes were analyzed. EVs alone regulated the expression of numerous genes related to inflammation and signaling. In combination, the effects of EVs and TNF were additive, antagonistic, or independent. The differential effects of EVs and TNF or their simultaneous presence were also validated by Taqman assays and ELISA, and by testing different populations of purified EVs. In the case of the paramount chemokine IL-8, we were able to demonstrate a synergistic upregulation by purified EVs and TNF. Our data suggest that neglecting the modulating role of EVs on the effects of soluble mediators may skew experimental results. On the other hand, considering the combined effects of cytokines and EVs may prove therapeutically useful by targeting both compartments at the same time.
Enyedi P.,Semmelweis University |
Czirjak G.,Semmelweis University
Physiological Reviews | Year: 2010
Two-pore domain K+ (K2P) channels give rise to leak (also called background) K+ currents. The well-known role of background K+ currents is to stabilize the negative resting membrane potential and counterbalance depolarization. However, it has become apparent in the past decade (during the detailed examination of the cloned and corresponding native K2P channel types) that this primary hyperpolarizing action is not performed passively. The K2P channels are regulated by a wide variety of voltage-independent factors. Basic physicochemical parameters (e.g., pH, temperature, membrane stretch) and also several intracellular signaling pathways substantially and specifically modulate the different members of the six K2P channel subfamilies (TWIK, TREK, TASK, TALK, THIK, and TRESK). The deep implication in diverse physiological processes, the circumscribed expression pattern of the different channels, and the interesting pharmacological profile brought the K2P channel family into the spotlight. In this review, we focus on the physiological roles of K2P channels in the most extensively investigated cell types, with special emphasis on the molecular mechanisms of channel regulation. Copyright © 2010 the American Physiological Society.